TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07098403: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase Ⅲ Study to Evaluate the Efficacy and Safety of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07098403 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07098403 Rescue Dossier →